Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Q2 earnings exceeded expectations, and although the full-year guidance has been raised, concerns remain! Sales of the oral Wegovy drug are sluggish, and the path to returning to growth is still shrouded in shadow.

Despite Novo Nordisk A/S Sponsored ADR Class B (NVO.US) reporting better-than-expected results for the second quarter of 2026 and raising its full-year guidance, it has not addressed Wall Street's most pressing concernwhether this Danish pharmaceutical giant can chart a clear path back to sustainable growth amidst intensifying competition in the weight loss drug market. The financial report indicated that at fixed exchange rates, Novo Nordisk A/S Sponsored ADR Class B's adjusted sales in the second quarter increased by 7% year-over-year to 78.488 billion Danish kroner (approximately $12.09 billion), surpassing the market expectation of $11.35 billion; adjusted operating profit grew by 11% year-over-year to 33.389 billion Danish kroner, also exceeding market expectations. In the second quarter, sales of Wegovy injections reached 19.48 billion Danish kroner, where despite continued growth in the U.S. market, sales fell by 22% year-over-year due to pricing factors; Ozempic sales amounted to 31.38 billion Danish kroner. Notably, the much-watched sales of the oral Wegovy drug in the second quarter were 3.22 billion Danish kroner, slightly below the market expectation of 3.27 billion Danish kroner. As Novo Nordisk A/S Sponsored ADR Class B strives to reclaim market share in obesity drugs from Eli Lilly (LLY.US), the rapid growth in the initial launch of Wegovy's oral form had fueled investor hopes for explosive growth. However, the latest results have raised market concerns about the company's long-term competitiveness. CEO Mike Doustdar explained that the demand for the oral Wegovy was offset by lower prices. He noted that since its launch in January this year, prescriptions for the oral Wegovy have cumulatively surpassed 5 million; as of the week of July 17, the total weekly prescriptions in the U.S. exceeded 265,000. He also stated that the next market for the oral Wegovy will be Germany, the largest pharmaceutical market in Europe. Mike Doustdar stated in a press release: "The Wegovy product line remains a key growth driver for Novo Nordisk A/S Sponsored ADR Class B in 2026. The rapid adoption of the oral Wegovy in the U.S. market is a primary driving factor. Meanwhile, early promotion performances in markets outside the U.S. are encouraging. The launch of the high-dose version of Wegovy will also further drive growth." However, at the same time, Novo Nordisk A/S Sponsored ADR Class B cautioned that its U.S. business would face declining sales. The company attributed this to a combination of factors, including: slowing prescription trends for GLP-1 injectables, ongoing intensified competition, a narrowing coverage of obesity medication under Medicaid, and declining actual selling prices in the U.S. marketpartly stemming from a "most-favored-nation" drug pricing agreement with the Trump administration. Looking ahead, Novo Nordisk A/S Sponsored ADR Class B has raised its full-year guidance for 2026. It now expects, at fixed exchange rates, adjusted sales and operating profit to decline by 6% to flat, an improvement from the previous guidance of a decline of 4% to 12% for both metrics. Novo Nordisk A/S Sponsored ADR Class B stated that the improved outlook primarily reflects increased expectations for GLP-1 product sales growth. However, the market did not react with enthusiasm to Novo Nordisk A/S Sponsored ADR Class B's raised full-year guidance. Citigroup analysts remarked, "Overall, there is nothing exciting." Jefferies Financial Group Inc. stated that the consensus sales expectations have little room for further upward adjustment after this guidance revision. Mizuho Securities medical industry strategist Jared Holz noted that this guidance raise "is certainly not thrilling." He emphasized that the "lack of upside for the oral Wegovy compared to market expectations" puts pressure on the stock price. Novo Nordisk A/S Sponsored ADR Class B is in fierce competition with its American rival Eli Lilly for market share in the weight loss drug sector. It is estimated that the obesity drug market will reach $120 billion annually by 2030. Eli Lilly is leading in market share with its Zepbound and Mounjaro injectables. The release of Wegovy oral and higher-dose injectable versions by Novo Nordisk A/S Sponsored ADR Class B is viewed as a core initiative to regain market position. An indication of the increasing competition between the two pharmaceutical giants is that Novo Nordisk A/S Sponsored ADR Class B filed a lawsuit against Eli Lilly on July 21, accusing the American company of misleading behavior in the advertising of its Zepbound and Mounjaro injectable drugs. Eli Lilly has denied the allegations. In addition to the sales momentum of its existing weight loss drugs not matching similar products from Eli Lilly, Novo Nordisk A/S Sponsored ADR Class B's experimental drug CagriSema failed to achieve comparable blood sugar control results to Zepbound in a large trial. This marks the second time this year that the new drug has failed to compete with Eli Lilly's star product. Claus Henrik Johansen, CEO of Global Health Invest, commented that this once again presents "a blemish on CagriSema's reputation." Furthermore, Novo Nordisk A/S Sponsored ADR Class B has also faced significant setbacks in the development of other drug pipelines. The company announced last Friday that its investigational cardiovascular drug ziltivekimab failed to meet its primary endpoint in a large late-stage clinical trial, failing to demonstrate a reduction in the risk of major cardiovascular events for patients. This failure highlights Novo Nordisk A/S Sponsored ADR Class B's high reliance on the GLP-1 weight loss drug business and increases uncertainty for future growth.